Buys | $370,967 | 10 | 37 |
Sells | $5,860,158 | 17 | 63 |
Heron Patrick J | director | 8 | $269,767 | 0 | $0 | $269,767 |
BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 2 | $101,200 | 0 | $0 | $101,200 |
Ramasastry Saira | director | 0 | $0 | 1 | $128,400 | $-128,400 |
Howe Jolanda | SVP, GLOBAL CONTROLLER | 0 | $0 | 5 | $257,150 | $-257,150 |
Quan Joanne | CHIEF MEDICAL OFFICER | 0 | $0 | 1 | $319,598 | $-319,598 |
Vig Pamela | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 1 | $1.04M | $-1.04M |
Radovich Peter | PRESIDENT AND COO | 0 | $0 | 5 | $1.15M | $-1.15M |
Peetz Christopher | CHIEF EXECUTIVE OFFICER | 0 | $0 | 4 | $2.96M | $-2.96M |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, …
Over the last 12 months, insiders at Mirum Pharmaceuticals, Inc. have bought $370,967 and sold $5.86M worth of Mirum Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Mirum Pharmaceuticals, Inc. have bought $1.37M and sold $5.03M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $269,767. BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) — $101,200.
The last purchase of 963 shares for transaction amount of $42,155 was made by Heron Patrick J (director) on 2025‑03‑11.
2025-03-11 | Heron Patrick J | director | 963 0.002% | $43.77 | $42,155 | +1.76% | ||
2025-03-10 | Heron Patrick J | director | 1,335 0.0027% | $42.97 | $57,363 | +3.60% | ||
2025-03-07 | Heron Patrick J | director | 580 0.0012% | $43.21 | $25,064 | +1.96% | ||
2025-03-06 | Heron Patrick J | director | 1,335 0.0027% | $43.89 | $58,597 | +1.29% | ||
2025-03-05 | Heron Patrick J | director | 267 0.0005% | $44.55 | $11,894 | -1.93% | ||
2025-03-04 | Sale | Radovich Peter | PRESIDENT AND COO | 14,850 0.0305% | $45.58 | $676,928 | -2.65% | |
2025-03-04 | Heron Patrick J | director | 1,335 0.0027% | $45.57 | $60,830 | -2.65% | ||
2025-03-03 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 40,000 0.0836% | $46.91 | $1.88M | -3.70% | |
2025-02-03 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 9,102 0.0187% | $48.22 | $438,921 | +3.23% | |
2025-02-03 | Sale | Radovich Peter | PRESIDENT AND COO | 2,627 0.0054% | $48.22 | $126,681 | +3.23% | |
2025-02-03 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 1,064 0.0022% | $48.22 | $51,309 | +3.23% | |
2025-01-24 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 6,837 0.0143% | $47.92 | $327,658 | +2.84% | |
2025-01-24 | Sale | Radovich Peter | PRESIDENT AND COO | 3,177 0.0066% | $47.92 | $152,256 | +2.84% | |
2025-01-24 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 902 0.0019% | $47.92 | $43,228 | +2.84% | |
2025-01-17 | Sale | Quan Joanne | CHIEF MEDICAL OFFICER | 6,969 0.0143% | $45.86 | $319,598 | +3.51% | |
2025-01-07 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 7,489 0.0159% | $42.82 | $320,644 | +15.22% | |
2025-01-07 | Sale | Radovich Peter | PRESIDENT AND COO | 1,998 0.0043% | $42.82 | $85,545 | +15.22% | |
2025-01-07 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 750 0.0016% | $42.82 | $32,111 | +15.22% | |
2024-11-14 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 2,500 0.0053% | $47.10 | $117,752 | -2.66% | |
2024-09-18 | Heron Patrick J | director | 115 0.0002% | $37.40 | $4,301 | +13.59% |
Heron Patrick J | director | 168123 0.343% | $7.49M | 13 | 0 | +0.01% |
Peetz Christopher | CHIEF EXECUTIVE OFFICER | 115920 0.2365% | $5.17M | 4 | 9 | +41.16% |
Vig Pamela | CHIEF SCIENTIFIC OFFICER | 27406 0.0559% | $1.22M | 1 | 6 | +53.04% |
BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 14000 0.0286% | $623,840.00 | 3 | 0 | <0.0001% |
BARRIS PETER J | 10 percent owner | 4186243 8.5409% | $186.54M | 1 | 0 | +5.09% |
$66,492,695 | 135 | 27.65% | $2.03B | |
$1,376,668 | 53 | 18.46% | $2.27B | |
Mirum Pharmaceuticals, Inc. (MIRM) | $224,267,561 | 40 | 26.78% | $2.18B |
$62,927,079 | 29 | 14.02% | $2.25B | |
$150,253,463 | 26 | -52.83% | $2.22B |
Increased Positions | 115 | +65.34% | 4M | +6.79% |
Decreased Positions | 74 | -42.05% | 3M | -6.47% |
New Positions | 41 | New | 1M | New |
Sold Out Positions | 14 | Sold Out | 637,134 | Sold Out |
Total Postitions | 217 | +23.3% | 53M | +0.31% |
Frazier Life Sciences Management, L.P. | $312,554.00 | 13.41% | 6.57M | 0 | 0% | 2024-12-31 |
Janus Henderson Group Plc | $217,949.00 | 9.35% | 4.58M | +101,358 | +2.26% | 2024-12-31 |
Blackrock, Inc. | $163,385.00 | 7.01% | 3.43M | +66,471 | +1.97% | 2024-12-31 |
Bvf Inc/Il | $133,030.00 | 5.71% | 2.8M | -279,394 | -9.08% | 2024-12-31 |
Eventide Asset Management, Llc | $124,012.00 | 5.32% | 2.61M | -838,425 | -24.34% | 2024-12-31 |
Vanguard Group Inc | $115,345.00 | 4.95% | 2.42M | -71,378 | -2.86% | 2024-12-31 |
Citadel Advisors Llc | $71,887.00 | 3.08% | 1.51M | +119,774 | +8.61% | 2024-12-31 |
Novo Holdings A/S | $71,355.00 | 3.06% | 1.5M | 0 | 0% | 2024-12-31 |
Rock Springs Capital Management Lp | $70,002.00 | 3% | 1.47M | -108,924 | -6.89% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $67,679.00 | 2.9% | 1.42M | +138,623 | +10.79% | 2024-12-31 |